0001638287 false 0001638287 2022-09-27 2022-09-27 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): September 27, 2022

 

NeuroBo Pharmaceuticals, Inc.

(Exact name of Registrant as Specified in Its Charter)

 

 

Delaware   001-37809   47-2389984

(State or other jurisdiction

of incorporation)

 ​

(Commission

File Number)

 ​

(IRS Employer

Identification No.)
​ ​ ​ ​ ​

200 Berkeley Street, 19th Floor

Boston, Massachusetts 02116

(Address of principal executive offices, including Zip Code)

 

Registrant’s Telephone Number, Including Area Code: (857) 702-9600

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

  

Title of each class  

Trading
Symbol(s)

  

Name of each exchange on which registered
Common Stock, par value $0.001 per share   NRBO   The Nasdaq Stock Market LLC

  

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company  ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

 

 

 

 

 

 

 

Item 8.01 Other Events

 

On September 27, 2022, NeuroBo Pharmaceuticals, Inc. (the “Company”) received formal notification (the “Notification”) from The Nasdaq Stock Market LLC (“Nasdaq”) confirming that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), which requires issuers listed on The Nasdaq Capital Market to maintain a closing bid price of at least $1.00 per share, and that the Company satisfies all other applicable criteria for continued listing on The Nasdaq Capital Market. As a result of the determination, the listing matter is now closed.

 

A press release issued by the Company on September 29, 2022 regarding the Notification is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

    The following exhibits are filed as part of this report:

 

No.   Description
     
99.1   Press Release dated September 29, 2022, entitled “NeuroBo Pharmaceuticals, Inc. Compliant with All Applicable Nasdaq Listing Criteria”
     
104   Cover Page Interactive Data File (embedded within Inline XBRL document).

 

- 2 -

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

​

​ NeuroBo Pharmaceuticals, Inc.
   
Date: September 29, 2022 By: /s/ Gil Price, M.D.
​ ​ Gil Price, M.D.
​ ​ President and Chief Executive Officer

 

- 3 -

 

NeuroBo Pharmaceuticals (NASDAQ:NRBO)
Historical Stock Chart
From Dec 2022 to Jan 2023 Click Here for more NeuroBo Pharmaceuticals Charts.
NeuroBo Pharmaceuticals (NASDAQ:NRBO)
Historical Stock Chart
From Jan 2022 to Jan 2023 Click Here for more NeuroBo Pharmaceuticals Charts.